Tivozanib和索拉非尼作为最初的靶向治疗转移性肾细胞癌患者:第三期临床试验的结果。

文章的细节

引用

复制到剪贴板

Motzer RJ, Nosov D,艾森T, Bondarenko案我Lesovoy V, Lipatov O, Tomczak P, Lyulko O, Alyasova, Harza M, Kogan M, Alekseev,斯特恩伯格CN, Szczylik C, D内殿,同样C, Krivoshik, Strahs, Esteves B, Berkenblit, Hutson TE

Tivozanib和索拉非尼作为最初的靶向治疗转移性肾细胞癌患者:第三期临床试验的结果。

肿瘤防治杂志。2013年10月20日,31日(30):3791 - 9。doi: 10.1200 / JCO.2012.47.4940。Epub 2013年9月9日。

PubMed ID

24019545 (在PubMed

]

文摘

目的:Tivozanib是一个强有力的和选择性的血管内皮生长因子受体酪氨酸激酶抑制剂1 (VEGFR1), 2,和3。这第三阶段试验相比tivozanib与索拉非尼患者最初的靶向治疗转移性肾细胞癌(RCC)。患者和方法:患者转移碾压混凝土,一个透明细胞组件,切除之前,可衡量的疾病,0或1之前治疗转移性RCC被随机分配到tivozanib或索拉非尼。之前VEGF-targeted疗法和哺乳动物雷帕霉素靶抑制剂是不允许的。主要终点是无进展生存(PFS)由独立审查。结果:共有517名患者被随机分配到tivozanib (n = 260)或索拉非尼(n = 257)。PFS与索拉非尼与tivozanib超过总人口(中位数,11.9 v 9.1个月;风险比[HR], 0.797;95%可信区间,0.639 - 0.993;P = .042)。 One hundred fifty-six patients (61%) who progressed on sorafenib crossed over to receive tivozanib. The final overall survival (OS) analysis showed a trend toward longer survival on the sorafenib arm than on the tivozanib arm (median, 29.3 v 28.8 months; HR, 1.245; 95% CI, 0.954 to 1.624; P = .105). Adverse events (AEs) more common with tivozanib than with sorafenib were hypertension (44% v 34%) and dysphonia (21% v 5%). AEs more common with sorafenib than with tivozanib were hand-foot skin reaction (54% v 14%) and diarrhea (33% v 23%). CONCLUSION: Tivozanib demonstrated improved PFS, but not OS, and a differentiated safety profile, compared with sorafenib, as initial targeted therapy for metastatic RCC.

DrugBank数据引用了这篇文章

药物靶点

药物	目标	类	生物	药理作用	行动
Tivozanib	血小板源生长因子受体β	蛋白质	人类	是的	抑制剂	细节
Tivozanib	FLT3 Receptor-type酪氨酸受体激酶	蛋白质	人类	未知的	抑制剂	细节